<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04505956</url>
  </required_header>
  <id_info>
    <org_study_id>Moses Ureteroscopy RCT</org_study_id>
    <nct_id>NCT04505956</nct_id>
  </id_info>
  <brief_title>A Comparison of Ureteroscopic Treatment of Nephrolithiasis With and Without Moses Technology</brief_title>
  <official_title>Prospective Randomized Double Blind Clinical Trial to Compare Holmium Laser Lithotripsy With and Without Moses Laser Technology for the Ureteroscopic Treatment of Nephrolithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Flexible ureteroscopy is characterized as first-line therapy for the treatment of renal&#xD;
      stones &lt; 2 cm in size. This involves passing a flexible endoscope into the renal pelvis&#xD;
      through the urethra, bladder and ureter in a retrograde fashion. Holmium: YAG laser remains&#xD;
      the preferred energy modality to subsequently break stones of this size into fragments small&#xD;
      enough to remove or pass spontaneously through the ureter. Advances in the understanding of&#xD;
      laser energy delivery have led to the recent commercialization of the &quot;Moses Effect&quot; - the&#xD;
      creation of vapor bubbles/cavities between the laser fiber tip and the target through which&#xD;
      laser energy can more efficiently travel. Lumenis was the first to optimize this laser&#xD;
      phenomenon and market it as &quot;Moses Technology&quot; in their Lumenis Pulse P120H laser system.&#xD;
      This system is already FDA approved through the 510K pathway and is commercially available.&#xD;
      The purpose of this study is to evaluate the potential of Moses laser technology to reduce&#xD;
      operative time compared to non-Moses settings for ureteroscopic treatment of nephrolithiasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is ongoing debate on the optimal means of laser stone fragmentation, and Moses&#xD;
      technology is the latest advancement to raise questions regarding clinical utility. Initial&#xD;
      preclinical studies demonstrated significantly reduced stone retropulsion and higher stone&#xD;
      ablation volume with Moses technology, leading to the conclusion that the system allows more&#xD;
      efficient laser lithotripsy. Human studies also showed that laser lithotripsy with Moses&#xD;
      technology utilized laser energy in less time for stone fragmentation: 10.0 (2.6-15.0) min&#xD;
      without vs 6.0 (2.8-13.0) min with Moses technology.&#xD;
&#xD;
      Others have evaluated the cost effectiveness of Moses technology in their own cohort of 40&#xD;
      patients who underwent standard laser lithotripsy by comparing a 35% projected decrease in&#xD;
      procedure time against the cost of the Moses laser fiber and machine. Mean stone size was&#xD;
      10.2 mm in this group of patients, and mean lasing time was 3.0 minutes. While a significant&#xD;
      positive association was seen between stone size and laser time, cost analysis failed to show&#xD;
      a benefit in using Moses technology across sizes.&#xD;
&#xD;
      To date, there are limited clinical data obtained through rigorous study methodology. In&#xD;
      addition, knowledge gaps remain regarding the effect of Moses technology on other clinically&#xD;
      meaningful outcomes such as stone-free rate. Therefore, the investigators propose a&#xD;
      multi-center, prospective, randomized, double blind clinical trial to further assess the&#xD;
      effect of Moses technology for lithotripsy. The investigators aim to study a broader range of&#xD;
      outcomes which will be facilitated by being the largest study to date. The investigators also&#xD;
      aim to study novel outcomes such as grading retropulsion and visibility by independent&#xD;
      blinded review as well as effects of Moses technology on independently reducing surgeon&#xD;
      burnout. Indeed, a randomized, double blind clinical trial evaluating Moses technology in 66&#xD;
      patients undergoing ureteroscopy was presented as a 2018 European Association of Urology&#xD;
      abstract. While this single center study demonstrated safety and reduced fragmentation time&#xD;
      as well as procedure time using Moses technology, it did not show a significant difference in&#xD;
      stone-free rates. This study is also yet to be published as a manuscript.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative Time</measure>
    <time_frame>Beginning to end of procedure time</time_frame>
    <description>Total operative times between Moses holmium laser lithotripsy and non-Moses holmium laser lithotripsy in the ureteroscopic treatment of renal stones using a dusting technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stone retropulsion</measure>
    <time_frame>First 20 seconds of laser lithotripsy</time_frame>
    <description>Stone movement during laser lithotripsy will be recorded on video and graded on a Likert scale by blinded reviewers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Nephrolithiasis</condition>
  <arm_group>
    <arm_group_label>Moses Laser Lithotripsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique using Moses laser technology.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Laser Lithotripsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holmium laser lithotripsy with Moses Technology</intervention_name>
    <description>Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.</description>
    <arm_group_label>Moses Laser Lithotripsy</arm_group_label>
    <other_name>Moses Laser Lithotripsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holmium laser lithotripsy without Moses Technology</intervention_name>
    <description>Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.</description>
    <arm_group_label>Standard Laser Lithotripsy</arm_group_label>
    <other_name>Standard Laser Lithotripsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Solitary renal stone 8 to 20 mm in size or in the case of multiple stones the&#xD;
             conglomerate diameter (additive maximal diameter of all stones on axial imaging of&#xD;
             computed tomography) of 8-20 mm is required&#xD;
&#xD;
          -  Must be a suitable operative candidate for flexible ureteroscopy per urologic&#xD;
             guidelines&#xD;
&#xD;
          -  Must be 18 years or older&#xD;
&#xD;
          -  Must be able to give consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant stones in the ureter&#xD;
&#xD;
          -  Prior ipsilateral upper urinary tract reconstructive procedures or history of&#xD;
             ipsilateral ureteral stricture&#xD;
&#xD;
          -  Prior radiotherapy to the abdomen or pelvis&#xD;
&#xD;
          -  Neurogenic bladder or spinal cord injury&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Untreated UTI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole L Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole L Miller, MD</last_name>
    <phone>(615) 322-3807</phone>
    <email>nicole.miller@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Stern, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Bechis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ojas Shah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lipkin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sriharan Sivalingam, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Miller, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Naren Nimmagadda, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, Pace KT, Pais VM Jr, Pearle MS, Preminger GM, Razvi H, Shah O, Matlaga BR. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART II. J Urol. 2016 Oct;196(4):1161-9. doi: 10.1016/j.juro.2016.05.091. Epub 2016 May 27.</citation>
    <PMID>27238615</PMID>
  </reference>
  <reference>
    <citation>Turk C, Petrik A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T. EAU Guidelines on Interventional Treatment for Urolithiasis. Eur Urol. 2016 Mar;69(3):475-82. doi: 10.1016/j.eururo.2015.07.041. Epub 2015 Sep 4.</citation>
    <PMID>26344917</PMID>
  </reference>
  <reference>
    <citation>Ventimiglia E, Traxer O. What Is Moses Effect: A Historical Perspective. J Endourol. 2019 May;33(5):353-357. doi: 10.1089/end.2019.0012.</citation>
    <PMID>30892062</PMID>
  </reference>
  <reference>
    <citation>Law KE, Lowndes BR, Kelley SR, Blocker RC, Larson DW, Hallbeck MS, Nelson H. NASA-Task Load Index Differentiates Surgical Approach: Opportunities for Improvement in Colon and Rectal Surgery. Ann Surg. 2020 May;271(5):906-912. doi: 10.1097/SLA.0000000000003173.</citation>
    <PMID>30614878</PMID>
  </reference>
  <reference>
    <citation>Dias RD, Ngo-Howard MC, Boskovski MT, Zenati MA, Yule SJ. Systematic review of measurement tools to assess surgeons' intraoperative cognitive workload. Br J Surg. 2018 Apr;105(5):491-501. doi: 10.1002/bjs.10795. Epub 2018 Feb 21.</citation>
    <PMID>29465749</PMID>
  </reference>
  <reference>
    <citation>Elhilali MM, Badaan S, Ibrahim A, Andonian S. Use of the Moses Technology to Improve Holmium Laser Lithotripsy Outcomes: A Preclinical Study. J Endourol. 2017 Jun;31(6):598-604. doi: 10.1089/end.2017.0050. Epub 2017 Apr 25.</citation>
    <PMID>28340540</PMID>
  </reference>
  <reference>
    <citation>Ibrahim A, Badaan S, Elhilali MM, Andonian S. Moses technology in a stone simulator. Can Urol Assoc J. 2018 Apr;12(4):127-130. doi: 10.5489/cuaj.4797. Epub 2017 Dec 22.</citation>
    <PMID>29319478</PMID>
  </reference>
  <reference>
    <citation>Mullerad M, Aguinaga JRA, Aro T, Kastin A, Goldin O, Kravtsov A, Assadi A, Badaan S, Amiel GE. Initial Clinical Experience with a Modulated Holmium Laser Pulse-Moses Technology: Does It Enhance Laser Lithotripsy Efficacy? Rambam Maimonides Med J. 2017 Oct 16;8(4):e0038. doi: 10.5041/RMMJ.10315.</citation>
    <PMID>28914602</PMID>
  </reference>
  <reference>
    <citation>Stern KL, Monga M. The Moses holmium system - time is money. Can J Urol. 2018 Jun;25(3):9313-9316.</citation>
    <PMID>29900818</PMID>
  </reference>
  <reference>
    <citation>Humphreys MR, Shah OD, Monga M, Chang YH, Krambeck AE, Sur RL, Miller NL, Knudsen BE, Eisner BH, Matlaga BR, Chew BH. Dusting versus Basketing during Ureteroscopy-Which Technique is More Efficacious? A Prospective Multicenter Trial from the EDGE Research Consortium. J Urol. 2018 May;199(5):1272-1276. doi: 10.1016/j.juro.2017.11.126. Epub 2017 Dec 16.</citation>
    <PMID>29253579</PMID>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>March 9, 2023</last_update_submitted>
  <last_update_submitted_qc>March 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Nicole L. Miller</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Ureteroscopy</keyword>
  <keyword>Nephrolithiasis</keyword>
  <keyword>Kidney Stone</keyword>
  <keyword>Lithotripsy</keyword>
  <keyword>Holmium</keyword>
  <keyword>Moses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04505956
org study id: Moses Ureteroscopy RCT
nct id: NCT04505956
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: Yes
is us export: No
Flexible ureteroscopy is characterized as first-line therapy for the treatment of renal
      stones < 2 cm in size. This involves passing a flexible endoscope into the renal pelvis
      through the urethra, bladder and ureter in a retrograde fashion. Holmium: YAG laser remains
      the preferred energy modality to subsequently break stones of this size into fragments small
      enough to remove or pass spontaneously through the ureter. Advances in the understanding of
      laser energy delivery have led to the recent commercialization of the "Moses Effect" - the
      creation of vapor bubbles/cavities between the laser fiber tip and the target through which
      laser energy can more efficiently travel. Lumenis was the first to optimize this laser
      phenomenon and market it as "Moses Technology" in their Lumenis Pulse P120H laser system.
      This system is already FDA approved through the 510K pathway and is commercially available.
      The purpose of this study is to evaluate the potential of Moses laser technology to reduce
      operative time compared to non-Moses settings for ureteroscopic treatment of nephrolithiasis.
There is ongoing debate on the optimal means of laser stone fragmentation, and Moses
      technology is the latest advancement to raise questions regarding clinical utility. Initial
      preclinical studies demonstrated significantly reduced stone retropulsion and higher stone
      ablation volume with Moses technology, leading to the conclusion that the system allows more
      efficient laser lithotripsy. Human studies also showed that laser lithotripsy with Moses
      technology utilized laser energy in less time for stone fragmentation: 10.0 (2.6-15.0) min
      without vs 6.0 (2.8-13.0) min with Moses technology.

      Others have evaluated the cost effectiveness of Moses technology in their own cohort of 40
      patients who underwent standard laser lithotripsy by comparing a 35% projected decrease in
      procedure time against the cost of the Moses laser fiber and machine. Mean stone size was
      10.2 mm in this group of patients, and mean lasing time was 3.0 minutes. While a significant
      positive association was seen between stone size and laser time, cost analysis failed to show
      a benefit in using Moses technology across sizes.

      To date, there are limited clinical data obtained through rigorous study methodology. In
      addition, knowledge gaps remain regarding the effect of Moses technology on other clinically
      meaningful outcomes such as stone-free rate. Therefore, the investigators propose a
      multi-center, prospective, randomized, double blind clinical trial to further assess the
      effect of Moses technology for lithotripsy. The investigators aim to study a broader range of
      outcomes which will be facilitated by being the largest study to date. The investigators also
      aim to study novel outcomes such as grading retropulsion and visibility by independent
      blinded review as well as effects of Moses technology on independently reducing surgeon
      burnout. Indeed, a randomized, double blind clinical trial evaluating Moses technology in 66
      patients undergoing ureteroscopy was presented as a 2018 European Association of Urology
      abstract. While this single center study demonstrated safety and reduced fragmentation time
      as well as procedure time using Moses technology, it did not show a significant difference in
      stone-free rates. This study is also yet to be published as a manuscript.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double (Participant, Care Provider)
measure: Operative Time
time frame: Beginning to end of procedure time
description: Total operative times between Moses holmium laser lithotripsy and non-Moses holmium laser lithotripsy in the ureteroscopic treatment of renal stones using a dusting technique
measure: Stone retropulsion
time frame: First 20 seconds of laser lithotripsy
description: Stone movement during laser lithotripsy will be recorded on video and graded on a Likert scale by blinded reviewers
arm group label: Moses Laser Lithotripsy
arm group type: Experimental
description: Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique using Moses laser technology.
arm group label: Standard Laser Lithotripsy
arm group type: Active Comparator
description: Patients will have flexible URS performed in standard fashion, without deviation from the standard of care. Laser settings will be at the surgeons' discretion but will be within the range identified as standard for dusting technique (between 0.2-0.5 J and 40-80 Hz). The short pulse setting will be utilized for non-Moses settings.
intervention type: Device
intervention name: Holmium laser lithotripsy with Moses Technology
description: Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned on.
arm group label: Moses Laser Lithotripsy
other name: Moses Laser Lithotripsy
intervention type: Device
intervention name: Holmium laser lithotripsy without Moses Technology
description: Holmium laser energy will be delivered for the ureteroscopic fragmenting of kidney stones. Energy will be generated by the commercial available, FDA approved Lumenis PulseTM P120H laser system and Moses laser fiber. Renal stones will be fragmented using a dusting technique. Moses laser settings will be turned off.
arm group label: Standard Laser Lithotripsy
other name: Standard Laser Lithotripsy
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Nicole L Miller, MD
role: Principal Investigator
affiliation: Vanderbilt University Medical Center
last name: Nicole L Miller, MD
phone: (615) 322-3807
email: nicole.miller@vumc.org
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
country: United States
citation: Assimos D, Krambeck A, Miller NL, Monga M, Murad MH, Nelson CP, Pace KT, Pais VM Jr, Pearle MS, Preminger GM, Razvi H, Shah O, Matlaga BR. Surgical Management of Stones: American Urological Association/Endourological Society Guideline, PART II. J Urol. 2016 Oct;196(4):1161-9. doi: 10.1016/j.juro.2016.05.091. Epub 2016 May 27.
PMID: 27238615
citation: Turk C, Petrik A, Sarica K, Seitz C, Skolarikos A, Straub M, Knoll T. EAU Guidelines on Interventional Treatment for Urolithiasis. Eur Urol. 2016 Mar;69(3):475-82. doi: 10.1016/j.eururo.2015.07.041. Epub 2015 Sep 4.
PMID: 26344917
citation: Ventimiglia E, Traxer O. What Is Moses Effect: A Historical Perspective. J Endourol. 2019 May;33(5):353-357. doi: 10.1089/end.2019.0012.
PMID: 30892062
citation: Law KE, Lowndes BR, Kelley SR, Blocker RC, Larson DW, Hallbeck MS, Nelson H. NASA-Task Load Index Differentiates Surgical Approach: Opportunities for Improvement in Colon and Rectal Surgery. Ann Surg. 2020 May;271(5):906-912. doi: 10.1097/SLA.0000000000003173.
PMID: 30614878
citation: Dias RD, Ngo-Howard MC, Boskovski MT, Zenati MA, Yule SJ. Systematic review of measurement tools to assess surgeons' intraoperative cognitive workload. Br J Surg. 2018 Apr;105(5):491-501. doi: 10.1002/bjs.10795. Epub 2018 Feb 21.
PMID: 29465749
citation: Elhilali MM, Badaan S, Ibrahim A, Andonian S. Use of the Moses Technology to Improve Holmium Laser Lithotripsy Outcomes: A Preclinical Study. J Endourol. 2017 Jun;31(6):598-604. doi: 10.1089/end.2017.0050. Epub 2017 Apr 25.
PMID: 28340540
citation: Ibrahim A, Badaan S, Elhilali MM, Andonian S. Moses technology in a stone simulator. Can Urol Assoc J. 2018 Apr;12(4):127-130. doi: 10.5489/cuaj.4797. Epub 2017 Dec 22.
PMID: 29319478
citation: Mullerad M, Aguinaga JRA, Aro T, Kastin A, Goldin O, Kravtsov A, Assadi A, Badaan S, Amiel GE. Initial Clinical Experience with a Modulated Holmium Laser Pulse-Moses Technology: Does It Enhance Laser Lithotripsy Efficacy? Rambam Maimonides Med J. 2017 Oct 16;8(4):e0038. doi: 10.5041/RMMJ.10315.
PMID: 28914602
citation: Stern KL, Monga M. The Moses holmium system - time is money. Can J Urol. 2018 Jun;25(3):9313-9316.
PMID: 29900818
citation: Humphreys MR, Shah OD, Monga M, Chang YH, Krambeck AE, Sur RL, Miller NL, Knudsen BE, Eisner BH, Matlaga BR, Chew BH. Dusting versus Basketing during Ureteroscopy-Which Technique is More Efficacious? A Prospective Multicenter Trial from the EDGE Research Consortium. J Urol. 2018 May;199(5):1272-1276. doi: 10.1016/j.juro.2017.11.126. Epub 2017 Dec 16.
PMID: 29253579
responsible party type: Principal Investigator
investigator affiliation: Vanderbilt University Medical Center
investigator full name: Nicole L. Miller
investigator title: Associate Professor
mesh term: Nephrolithiasis
mesh term: Kidney Calculi
sharing ipd: No